Skip to main content
CLDX logo

Celldex Therapeutics, Inc. (CLDX) Stock: Price, Forecast & Analyst Target

Celldex Therapeutics, Inc. (CLDX) — MoonshotScore 21/100 (Weak band), calculated Nov 18, 2026. Price $27.55 (-1.75%), as of the Nov 18, 2026 trading session; market cap $2.16B.

Educational signal · not a buy or sell recommendation · How to read this

$27.55 −$0.49 (-1.75%) Market Cap $2.16B

Celldex Therapeutics, Inc. · CLDX · NASDAQ

Celldex Therapeutics, Inc. is a biopharmaceutical company specializing in the development of therapeutic monoclonal and bispecific antibodies for treating inflammatory diseases and various cancers.

Price as of Nov 18, 2026

Key Statistics

21 of 100

MoonshotScore v2 · Celldex Therapeutics (CLDX)

Weak
Business Quality Poor (11)
Financial Safety Fortress (84)
Valuation Rich (37)
Growth Durability Shrinking (5)
Momentum Quiet (56)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strong balance sheet, but bottom-tier quality, stalling growth and an expensive valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Shrinking; Momentum: Quiet.

  • quarterly revenue $121,000 (Q4 FY2025, quarter ended Dec 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z 14.33 · Piotroski F 1

Holding back: weak fundamentals, soft growth

Helping: balance-sheet strength

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CLDX (57 recorded, newest six shown)
RecordedScoreBand
22Weak
22Weak
22Weak
22Weak
21Weak
21Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$27.55
Change on the day-1.75%
52-week range$22.33 – $45.14
Market capitalisation$2.16B—
Price / earnings (trailing)-7.51
Shares traded on the day679.6K

Price & events

Other perspectives

Council score for Celldex Therapeutics (CLDX): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Negative
Financial Safety Strong
Valuation Weak
Growth Durability Negative
Momentum Neutral

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Four of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens, Simons-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Celldex Therapeutics (CLDX), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Celldex Therapeutics, Inc. (CLDX) is listed on NASDAQ. It employs 198 people and is led by Anthony S. Marucci. In Q4 FY2025 it reported revenue of $121,000 and net income of -$81M. The market values it at $2.16B.

2 · Latest results

What do the latest results show for Celldex Therapeutics (CLDX)?

Short answer · as of

The most recent reported quarter, Q4 FY2025, carried revenue of $121,000. Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 3 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2025$121,000-$81M-$1.22 (diluted)
Q1 FY2026$15,000-$79M-$1.18 (diluted)
Q2 FY2026$22,000-$74M-$0.94 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Celldex Therapeutics (CLDX)?

Short answer

The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z 14.33 · Piotroski F 1. Trailing ratios: ROE -49.5% · ROA -30.5% · current ratio 10.97.

Data-derived red flags

  • Negative return on equity (-49.5%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Celldex Therapeutics (CLDX)?

Short answer · as of

Current published price targets run low $45.00 · high $100.00 · consensus $66.80 · median $62.50 against a quoted price of $27.55 (as of Nov 18, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q4 FY2025) was filed Feb 25, 2026 — 8 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Celldex Therapeutics compare with its peers?

Short answer

Celldex Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eton Pharmaceuticals, Inc. (ETON) Same industry, near in market value$61.99 Nov 18, 2026$1.79B98 5-pillar Nov 18, 2026
Aurinia Pharmaceuticals Inc. (AUPH) Same industry, near in market value$15.13 Nov 18, 2026$2.03B97 5-pillar Nov 18, 2026
ADMA Biologics, Inc. (ADMA) Same industry, near in market value$13.56 Nov 18, 2026$3.01B97 5-pillar Nov 18, 2026
Nurix Therapeutics, Inc. (NRIX) Same industry, near in market value$14.10 Nov 18, 2026$1.54B97 5-pillar Nov 18, 2026
Harmony Biosciences Holdings, Inc. (HRMY) Same industry, near in market value$33.11 Nov 18, 2026$1.94B96 5-pillar Nov 18, 2026
Vericel Corporation (VCEL) Same industry, near in market value$58.26 Nov 19, 2026$2.97B95 5-pillar Nov 18, 2026
Veracyte, Inc. (VCYT) Same industry, near in market value$25.57 Nov 18, 2026$2.06B89 5-pillar Nov 18, 2026
Arcutis Biotherapeutics, Inc. (ARQT) Same industry, near in market value$27.61 Nov 18, 2026$3.49B89 5-pillar Nov 18, 2026
AnaptysBio, Inc. (ANAB) Same industry, near in market value$47.06 Nov 18, 2026$1.40B76 5-pillar Nov 18, 2026
Enliven Therapeutics, Inc. (ELVN) Same industry, near in market value$44.89 Nov 18, 2026$3.30B72 5-pillar Nov 18, 2026
ACADIA Pharmaceuticals Inc. (ACAD) Same industry, near in market value$17.83 Nov 18, 2026$3.08B68 5-pillar Nov 18, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Same industry, near in market value$26.62 Nov 18, 2026$3.42B66 5-pillar Nov 18, 2026
Celldex Therapeutics (CLDX) — this page$27.55$2.16B21

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$45.00 – $100.00
Consensus target
$66.80
Median target
$62.50

Consensus record · Captured .

Measured against a quoted price of $27.55 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Jun 25, 2026

Transactions
18
Identified insiders
18
Purchases
0
Sales
0
Other transactions
18

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CLDX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CLDX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Celldex Therapeutics (CLDX)?

Read these with our analysis →

What Investors Ask About Celldex Therapeutics (CLDX)

These answers are editorial: 1 of these 9 answers is drawn from the CLDX research dossier (written May 10, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for CLDX?

CLDX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is CLDX a good stock to buy?

Stock Expert AI does not rate CLDX buy, sell or hold. Celldex Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CLDX stock price today?

The last price recorded for Celldex Therapeutics, Inc. (CLDX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the CLDX price target?

The analyst consensus price target for Celldex Therapeutics, Inc. (CLDX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for CLDX?

Celldex Therapeutics, Inc. faces several risks, including regulatory challenges that could delay the approval of its drug candidates, high operational costs associated with ongoing research and development, and intense competition in the biotechnology sector.

What are the key factors to evaluate for CLDX?

Celldex Therapeutics, Inc. (CLDX) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. No dividend yield, consistent with typical biopharmaceutical companies reinvesting profits into R&D. Not financial advice.

How frequently does CLDX data refresh on this page?

CLDX's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CLDX's recent stock price performance?

Celldex Therapeutics, Inc. (CLDX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline with multiple promising drug candidates. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CLDX overvalued or undervalued right now?

Celldex Therapeutics, Inc. (CLDX) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 21 figures on this page — 14 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold CLDX

Funds in our ETF coverage that list CLDX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Simplify Propel Opportunities ETF (SURI)3.28%